CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Avastindrug
Likely dose
Avastin 10mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00545792
NCT00545792Phase 2Completed
CompareCT.gov

A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers

Dana-Farber Cancer Institute·interventional·Posted Oct 17, 2007·Updated Mar 15, 2017

In Brief

A Phase 2 clinical trial evaluating Avastin for Cervical Cancer and 4 related conditions. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This research study is evaluating a drug called avastin in combination with standard radiation as a possible treatment for treatment for recurrent pelvic-confined gynecological cancer (i.e. endometrial, cervical, vulvar, ovarian or vaginal cancers).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer, Carcinoma of the Vulva
CountriesUnited States
CollaboratorsGenentech, Inc., Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Lowell General Hospital, Saint Anne's Hospital

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 17, 2007
Enrollment StartMay 1, 2007
Primary CompletionNov 1, 2010
Study CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 18.7 years ago

Interventions

Avastindrug

Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.